Advertisement

Skeletal Radiology

, Volume 48, Issue 2, pp 209–218 | Cite as

The effects of granulocyte colony-stimulating factor on MR images of bone marrow

  • Liang GuEmail author
  • John E. Madewell
  • Rizwan Aslam
  • Bilal Mujtaba
Review Article
  • 170 Downloads

Abstract

Granulocyte colony-stimulating factor (G-CSF) analogs such as filgrastim/pegfilgrastim are increasingly used to enhance neutrophilic recovery after chemotherapy. It is widely known that, physiologically, pegfilgrastim stimulates marrow mitotic activity and induces marrow reconversion from fatty to cellular. However, there is limited literature discussing the effects of pegfilgrastim on musculoskeletal magnetic resonance imaging, with the consensus that marrow reconversion secondary to pegfilgrastim therapy is easily confounded with a malignant process, especially in patients with a history of cancer. We attempt to discuss the expected changes and MRI findings after pegfilgrastim therapy through a summary of current literature. Additionally, we provide images from our own practice to support the previously established findings. G-CSF-stimulated reconversion can appear as patchy expansions of baseline hematopoietic marrow, but can also appear to be diffusely homogeneous, adding to its ambiguity. We conclude that using a baseline MRI, clinical information, and assessing sequential MRI changes in conjunction with pegfilgrastim therapy may aid the differentiation between benign and pathological change. We expand our discussion to include the effects of novel technologies, such as whole-body MRI, chemical shift imaging, and contrast agents in helping the distinction.

Keywords

MRI Pegfilgrastim G-CSF Marrow Reconversion Neulasta 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant. 2003;32(4):399–404. Available from: http://www.nature.com/articles/1704156 CrossRefGoogle Scholar
  2. 2.
    Tegg EM, Tuck DM, Lowenthal RM, Marsden KA. The effect of G-CSF on the composition of human bone marrow. Clin Lab Haematol. 1999;21(4):265–70.  https://doi.org/10.1046/j.1365-2257.1999.00227.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Curran MP, Goa KL. Pegfilgrastim. Drugs. 2002;62(8):1207–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12010086 CrossRefGoogle Scholar
  4. 4.
    Proteins T, Drugs GI. Book review: biotechnology and biopharmaceuticals: transforming proteins and genes into drugs. Q Rev Biol. 2003;78(4):516.  https://doi.org/10.1086/382470.CrossRefGoogle Scholar
  5. 5.
    Inc. A. Neulasta (pegfilgrastim) injection prescribing information. Thousand Oaks; 2002.Google Scholar
  6. 6.
    Holmes F, O’Shaughnessy J, Vukelja S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in breast cancer. J Clin Oncol. 2002;20(3):727–31.  https://doi.org/10.1200/JCO.2002.20.3.727.CrossRefPubMedGoogle Scholar
  7. 7.
    Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3(6):1477–84.  https://doi.org/10.1002/cam4.344.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Farese AM, Macvittie TJ. Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs of Today. 2015;51(9):537–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26488033 PubMedGoogle Scholar
  9. 9.
    Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89(1):112–28.CrossRefGoogle Scholar
  10. 10.
    Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295–306.  https://doi.org/10.2165/11586040-000000000-00000.CrossRefPubMedGoogle Scholar
  11. 11.
    Mulcahy N. FDA Approves Pegfilgrastim Biosimilar for Cancer Infection Risk [Internet]. Medscape. 2018 [cited 2018 Jul 14]. Available from: https://www.medscape.com/viewarticle/897614
  12. 12.
    Ricci C, Cova M, Kang YS, Yang A, Rahmouni A, Scott WW, et al. Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study. Radiology. 1990 Oct;177(1):83–8.  https://doi.org/10.1148/radiology.177.1.2399343.CrossRefPubMedGoogle Scholar
  13. 13.
    McGee SJ, Havens AM, Shiozawa Y, Jung Y, Taichman RS. Effects of erythropoietin on the bone microenvironment. Growth Factors. 2012;30(1):22–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22117584 CrossRefGoogle Scholar
  14. 14.
    Ghanem N, Lerche A, Lohrmann C, Altehoefer C, Henke M, Langer M. Quantitative and semiquantitative evaluation of erythropoietin-induced bone marrow signal changes in lumbar spine MRI in patients with tumor anemia. Onkologie. 2007;30(6):303–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17551253 PubMedGoogle Scholar
  15. 15.
    Naples JC, Taljanovic MS, Graham ML, Hunter TB. Granulocyte-stimulating factor-induced bone marrow reconversion simulating neuroblastoma metastases on MRI: case report and literature review. Radiol Case Rep. 2007;2(1):5–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27303451 CrossRefGoogle Scholar
  16. 16.
    Smith SR, Williams CE, Davies JM, Edwards RH. Bone marrow disorders: characterization with quantitative MR imaging. Radiology. 1989;172(3):805–10.  https://doi.org/10.1148/radiology.172.3.2772192.CrossRefPubMedGoogle Scholar
  17. 17.
    Ollivier L, Gerber S, Vanel D, Brisse H, Leclère J. Improving the interpretation of bone marrow imaging in cancer patients. Cancer Imaging. 2006;6(1):194–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766564/ CrossRefGoogle Scholar
  18. 18.
    Hartman RP, Sundaram M, Okuno SH, Sim FH. Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings. AJR Am J Roentgenol. 2004;183(3):645–53.  https://doi.org/10.2214/ajr.183.3.1830645.CrossRefPubMedGoogle Scholar
  19. 19.
    Fletcher BD, Wall JE, Hanna SL. Effect of hematopoietic growth factors on MR images of bone marrow in children undergoing chemotherapy. Radiology. 1993;189(3):745–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7694312 CrossRefGoogle Scholar
  20. 20.
    Layer G, Sander W, Träber F, Block W, Ko Y, Ziske CG, et al. The diagnostic problems in magnetic resonance tomography of the bone marrow in patients with malignomas under G-CSF therapy. Radiologe. 2000;40(8):710–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11006941 CrossRefGoogle Scholar
  21. 21.
    Vanel D, Missenard G, Le Cesne A, Guinebretière JM. Red marrow recolonization induced by growth factors mimicking an increase in tumor volume during preoperative chemotherapy: MR study. J Comput Assist Tomogr. 1997;21(4):529–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9216756 CrossRefGoogle Scholar
  22. 22.
    Kouba M, Maaloufova J, Campr V, Belohlavek O, Drugova B. G-CSF stimulated islands of haematopoiesis mimicking disseminated malignancy on PET-CT and MRI scans in a patient with hypoplastic marrow disorder. Br J Haematol. 2005;130(6):807.  https://doi.org/10.1111/j.1365-2141.2005.05574.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Douis H, Davies AM, Jeys L, Sian P. Chemical shift MRI can aid in the diagnosis of indeterminate skeletal lesions of the spine. Eur Radiol. 2016;26(4):932–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26162578 CrossRefGoogle Scholar
  24. 24.
    Ghanem N, Altehoefer C, Kelly T, Lohrmann C, Winterer J, Schäfer O, et al. Whole-body MRI in comparison to skeletal scintigraphy in detection of skeletal metastases in patients with solid tumors. In Vivo. 2006;20(1):173–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16433049 PubMedGoogle Scholar
  25. 25.
    Ballon D, Watts R, Dyke JP, Lis E, Morris MJ, Scher HI, et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med. 2004;52(6):1234–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15562475 CrossRefGoogle Scholar
  26. 26.
    Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M. MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skelet Radiol. 1997;26(7):414–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9259099 CrossRefGoogle Scholar
  27. 27.
    Daldrup-Link HE, Henning T, Link TM. MR imaging of therapy-induced changes of bone marrow. Eur Radiol. 2007;17(3):743–61.  https://doi.org/10.1007/s00330-006-0404-1.CrossRefPubMedGoogle Scholar
  28. 28.
    Wood AJJ, Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327(1):28–35.  https://doi.org/10.1056/NEJM199207023270106.CrossRefGoogle Scholar

Copyright information

© ISS 2018

Authors and Affiliations

  1. 1.McGovern Medical SchoolUniversity of Texas Health Science Center at HoustonHoustonUSA
  2. 2.Department of Diagnostic Radiology, Division of Diagnostic ImagingUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations